Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

Pain Clinical Trial

Official title:

A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01885182
• Other study ID #: OXN10-CN-303
• Status: Completed
• Phase: Phase 3
• Start date: June 1, 2013
• Est. completion date: December 30, 2015

Study information

• Verified date: May 2019
• Source: Mundipharma (China) Pharmaceutical Co. Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain

Description:

This is a randomised, double-blind, double-dummy, parallel group study using OXN and OXY PR to treat moderate to severe, chronic cancer pain. Subjects with documented history of cancer pain that requires around the clock opioid therapy will be included. Subjects must have a medical history of constipation that was induced by, or worsened by their opioid therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 232
• Est. completion date: December 30, 2015
• Est. primary completion date: August 30, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Males & females, at least 18 years or older with a diagnosis of cancer.

Females less than one year post-menopausal must have a negative urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, & willing to use adequate & highly effective method of contraception throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (hormonal), sexual abstinence or vasectomised partner.

Subjects who are receiving WHO step II or Step III analgesic medication who have constipation induced, or worsened by their opioid medication, as shown by

1. the subject's medical need of regular intake of laxatives to have at least 3 bowel evacuations per week, or having less than 3 bowel evacuations when not taking a laxative, respectively.

2. the subject's self-assessment that their constipation was induced or worsened by their current pre-study opioid medication.

Documented history of moderate to severe, chronic cancer pain that requires around the-clock opioid therapy (starting dose of oxycodone PR between 20-80 mg/day) & are likely to benefit from WHO step III opioid therapy for the duration of the study. Subjects must be willing to discontinue their current opioid analgesic routine.

Opioid medication continue at a stable or nearly stable dose in the investigator's opinion during the treatment.

Subjects are willing to discontinue pre study laxative medication & take study specific laxative medication.

Subjects taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose & regimen throughout the study, & in the investigators opinion are willing & able to maintain adequate hydration.

Subjects willing & able (e.g. mental & physical condition) to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, & compliance with protocol requirements as evidenced by providing written, informed consent.

Subjects already taking non-opioid analgesics & all other concomitant medications (including those for the treatment of depression) are eligible to take part in the study. However, all concomitant medications that are considered necessary for the subject's welfare should be continued at a stable dose throughout the double-blind phase of the study & under the supervision of the investigator.

Expected survival time > 3 months.

With capability of reading, understanding & signing inform consent form & compliance with protocol requirements.

Exclusion Criteria Subjects that require a dose >80 mg/day oxycodone PR at the start of the double-blind phase.

Any history of hypersensitivity to oxycodone, naloxone, morphine, bisacodyl, related products & other ingredients.

Subjects with any situation in which opioids are contra-indicated, severe respiratory depression with hypoxia & or hypercapnia, severe chronic obstructive pulmonary disease, cor pulmonal, severe bronchial asthma, paralytic ileus.

Subjects with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression.

Evidence of clinically significant cardiovascular, renal, hepatic or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results & physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis & or interpretation of the study results.

Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), r-glutamyltransferase (GGT) or alkaline phosphatase levels (>3 times the upper limit of normal) or an abnormal total bilirubin & or creatinine level(s) (greater than 1.5 times the upper limit of normal).

Cyclic chemotherapy in the two weeks before the screening visit or planned during the core study that has shown in the past to influence bowel function. If subjects are having their first cycle of chemotherapy during the 2 weeks before the screening visit or during the double-blind phase of the study they should be excluded from the study.

Radiotherapy that, in the investigators opinion, would influence bowel function or pain during the double-blind phase of the study.

Subjects with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study.

Subjects with uncontrolled seizures.

Subjects with increased intracranial pressure.

In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication.

Subjects with myxoedema, not adequately treated hypothyroidism or Addisons disease.

Subjects who have a confirmed diagnosis of ongoing irritable bowel syndrome(IBS).

Surgery completed within 4 weeks prior to the start of the Screening Period, or planned surgery during the study that would influence pain or bowel function during the study or preclude completion of the study.

Subjects receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine).

Active alcohol or drug abuse & or history of opioid abuse.

Subjects suffering from diarrhoea & or opioid withdrawal.

Subjects presently taking, or who have taken, naloxone =30 days prior to the start of the Screening Period.

Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period), unless the subject is on data collection phase for Overall Survival.

Related Conditions & MeSH terms

• Cancer
• Cancer Pain
• Pain

Intervention

Drug:
• Oxycodone/Naloxone

• Oxycodone

Locations

Country	Name	City	State
China	307th hospital of Chinese People's medical sciences	Beijing
China	Beijing Cancer Hospital	Beijing
China	Beijing Friendship Hospital	Beijing
China	Beijing Hospital	Beijing
China	General Hospital of Beijing Military	Beijing
China	Pejing Union Medical College Hospital	Beijing
China	Peking University Third Hospital	Beijing
China	Jilin Cancer Hospital	Changchun	Jilin
China	Hubei Cancer Hospital	Changsha	Hubei
China	The second affiliated hospital of Dalian Medical university	Dalian	Liaoning
China	Fujian Medical University Union Hospital	Fuzhou	Fujian
China	Fuzhou General Hospital of Nanjing Military Command of PLA	Fuzhou	Fujian
China	Sun yat-sen univercity cancer center	Guangzhou	Guangdong
China	Sir Run Run Shaw Hospital	Hangzhou	Zhejiang
China	Harbin Cancer Hospital	Harbin	Heilongjiang
China	The central Hospital of Jinan	Jinan	Shandong
China	Jiangsu Cancer hospital	Nanjing	Jiangsu
China	The second hospital of Nanjing Medical university	Nanjing	Jiangsu
China	Shanghai Changzheng Hospital	Shanghai	Shanghai
China	The first people's hospital of shanghai	Shanghai
China	The sixth hospital of shanghai	Shanghai
China	The First Hospital of China Medical University	Shenyang	Liaoning
China	Hebei Medical University Fouth Hospital	Shijiazhuang	Hebei
China	Tianjin Cancer Hospital	Tianjin
China	Tongji Hospital Tongji Medical College of HUST	Wuhan	Hubei
China	Tangdu Hospital,Fourth Military Medical University	Xi'an	Shanxi
China	The First Affiliated Hospital of Xiamen University	Xiamen	Fujian
China	The First Affiliated Hospital of Xinxiang Medical University	Xinxiang	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Mundipharma (China) Pharmaceutical Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Change of BFI-Bowel Function Index at visit8	BFI is the mean of NAS for the following items: Ease of defecation; Feeling of incomplete bowel evacuation.; Personal judgment of constipation. NAS was a measure of 0-100 where 0 was easy/no difficulty/not at all and 100 was severe difficulty/very strong,total score range is 0-300.Do higher values represent a worse outcome.	Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
Primary	The Change of BPI-SF at visit8	Brief pain inventory short-form(BPI-SF) recorded at final visit assesses subject's average pain over the last 24 hours. score range is 0(no pain)-10(pain as bad as you can imagine).Do higher values represent a worse outcome.	Visit8, visit8 taking place at week 4 or after early discontinuation/withdrawal from study
Secondary	The Change of Symptoms of Constipation Based on Laxative Use From visit5 to visit8	At Visit 5(day7) and visit8(day28) number of bisacodyl taken(Number of laxative tablets took during the last 7 days (per week) and Daily number of laxative tablets took during the last 7 days (per day)*) for OXN PR and OXY PR groups.	visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
Secondary	The Change of Rescue Medication Use From visit5 to visit8	The average daily dose of rescue medication (Morphine Sulfate Tablet) for OXN PR group and OXY PR group at Visit 5(first week of double blind) and at Visit 8(last week of double blind).	visit 5 (week 1) to visit8 (week 4 or early discontinue/withdrawal from study)
Secondary	The Change of Modified Subjective Opiate Withdrawal Scale (SOWS) From Visit1 to visit3,visit1 to visit9	to compare the Modified SOWS's Change from Visit 1(day-10-0) to Visit 3(day1),Change from Visit 1 to Visit 9(day35).The SOWS was scored as the total of the 15 symptoms. each symptoms score is 0(not at all)-4(extremely).total score range is 0-60.Do higher values represent a better outcome.	Visit1(screening visit) to visit3 (day 1), visit1(screening visit) to visit9 (week 5)
Secondary	To Assess Quality of Life Based on EQ-5D	To assess quality of life based on EQ-5D by subjects evaluation via patient dairy.the quality of life based on EQ-5D at Visit1 (day-10-0) and end of treatment Visit8(day28). The scarc range is 0(the best state you can imagine)-100(the worst state you can imagine).Do higher values represent a worse outcome.	Visit1(screening visit) to Visit8 (week 4 or after early discontinuation/withdrawal from study)
Secondary	The Change of Individual Items in BPI-SF(Except for Pain in Average) by Visit	To compare the change of Brief pain inventory short-form (BPI-SF) 11 indivial items (except for pain in average) at visit2(day0) ,visit5(day7),visit6(day14),visit7(day21), visit8(day28). each item range (except for how much relief from treatment /medication last 24hours is 0-100%,do higher values represent a better outcome.) is 0-10, do higher values represent a worse outcome.	visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
Secondary	The Change of Bowel Movement by Visit	Number pf bowel movements(BM) and number of days the subjects had a bowel movement in the last 7 days before the study visit will be summarized at visit2(day0) ,visit5(day7),visit6(day14),visit7(day21), visit8(day28)..	visit2 (day 0) to visit8 (week 4 or early discontinue/withdrawal from study)
Secondary	The Chage of Symptoms of Constipation Based on Laxative Use From visit5 to visit8	At Visit5(day7) and visit8(day28) number of bisacodyl taken(Number of laxative tablets took during the last 7 days (per week) and Daily number of laxative tablets took during the last 7 days (per day)*) for OXN PR and OXY PR groups	visit 5 taking place at week 1 to visit8 taking place at week 4 or early discontinue/withdrawal from study where applicable